← Eichor
Study identifier: NCT06429969 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Metabolomic Profile of Vitreoretinal Diseases: an NMR-Based Approach Using Vitreous.

Condition: Vitreoretinal Disease  ·  Sponsor: Renmin Hospital of Wuhan University

PhaseN/A
Planned participants450
Who can joinAll sexes, 40 Years to 90 Years
Healthy volunteersNo

About this study

The goal of this observational study was to learn about metabolomics profiles in vitreoretinal diseases by nuclear magnetic resonance (NMR)using vitreous fluid. The main question it aimed to answer was abnormal biomarkers for common retinal diseases such as idiopathic macular hole(IMH), diabetic retinopathy(DR) and retinal detachment(RD). Participants would not be subjected to any intervention and the investigators would only collect preoperative information and remaining vitreous samples. The investigators divided the participants into groups with appropriate disease names based on the disease diagnosis, such as IMH group, DR group, and RD group. The MH group was used as a control group, investigators compared other groups to see the metabolomic abnormalities.

This description comes directly from the study's public registry record.

Talk to the study team

Liwei Cheng  ·  027-88041911  ·  wdrmiit@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Eye, Center, Renmin Hospital of Wuhan UniversityWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06429969